DYRKs-IN-1-hydrochloride-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEDYRKs-IN-1hydrochlorideCat.No.:HY-128758ACASNo.:1386980-55-7分?式:C??H??Cl?N?O?分?量:624.52作?靶點:DYRK作?通路:ProteinTyrosineKinase/RTK儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:20.83mg/mL(33.35mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.6012mL8.0061mL16.0123mL5mM0.3202mL1.6012mL3.2025mL10mM0.1601mL0.8006mL1.6012mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(3.33mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(3.33mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(3.33mM);ClearsolutionBIOLOGICALACTIVITY?物活性DYRKs-IN-1hydrochloride?種有效的DYRKs(雙特異性酪氨酸磷酸化調(diào)節(jié)激酶)抑制劑，對DYRK1A和DYRK1B的IC50分別為5nM和8nM。DYRKs-IN-1hydrochloride有抗腫瘤活性。IC50&TargetDYRK1ADYRK1B5nM(IC50)8nM(IC50)體外研究DYRKs-IN-1hydrochloride(compound30)increasesthecellularpotencyagainstthehumancolontumorcelllineSW620withanEC50of27nM[1].DYRKs-IN-1hydrochloride(Example183)isapotentDYRKsinhibitor[2].REFERENCES[1].AndersonK,etal.Pyrido[2,3-d]pyrimidines:discoveryandpreliminarySARofanovelseriesofDYRK1BandDYRK1Ainhibitors.BioorgMedChemLett.2013Dec15;23(24):6610-5.[2].KevinAnderson,etal.Pyridopyrimidines.US20120184542A1.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-82